Abstract: A job box includes a base defining a storage area, a lid coupled to the base and moveable between an open position, in which the storage area is accessible, and a closed position, in which the storage area in not accessible, and a charging station supported by the base. The station includes a first charging port configured to charge a battery pack of a first type, a second charging port configured to charge a battery pack of a second type, a light, and a first power outlet. The charging station is moveable relative to the job box to a plurality of different positions.

Abstract: A multi-actuator capable vehicle headrest includes a headrest support and a multi-cam release mechanism mounted to the headrest support. The multi-cam release mechanism includes a first cam and a second cam. A headrest shell member is pivotally mounted to the headrest support through the multi-cam release mechanism. An actuator is mounted to the headrest shell member. The actuator includes a first actuator portion operable to disengage the multi-cam release mechanism based on a first input and a second actuator portion operable to disengage the multi-cam release mechanism based on a second input that is distinct from the first input allowing the multi-actuator capable vehicle headrest to transition between a deployed configuration and a folded configuration.

Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.

Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g. controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.

Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g. controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.

Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.

Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.

Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.

Abstract: A method for configuring a computing device to use a communication protocol is provided. The method is performed by a computing device that includes a host processor coupled to a bus processor and to memory. The method includes receiving, by the host processor, a human-readable configuration file that includes parameters for communication using the communication protocol. The method additionally includes generating, by the host processor, at least one data structure based on the parameters in the human-readable configuration file. Additionally, the method includes providing, to the bus processor, memory location associated with the at least one data structure for use in communicating using the communication protocol.

Abstract: Systems, methods, and other embodiments associated with an integration application building tool are described. In one embodiment, a method includes providing data files including an adapter data file, a flow data file, and an environment data file. The adapter data file stores adapter data corresponding to a plurality of adapters for respective enterprise applications. An adapter for a given enterprise application enables the given enterprise application to exchange messages with a messaging system. The flow data file describes to a plurality of flows of messages, through the messaging system, between enterprise applications. The environment data file is configured to be populated with location data. The method includes, receiving an instance of location data and populating the environment data file. An adapter application comprising computer code is generated that, when executed, allows the enterprise application to exchange messages with the messaging system.

Abstract: Systems, methods, and other embodiments associated with an integration application building tool are described. In one embodiment, a method includes providing data files including an adapter data file, a flow data file, and an environment data file. The adapter data file stores adapter data corresponding to a plurality of adapters for respective enterprise applications. An adapter for a given enterprise application enables the given enterprise application to exchange messages with a messaging system. The flow data file describes to a plurality of flows of messages, through the messaging system, between enterprise applications. The environment data file is configured to be populated with location data. The method includes, receiving an instance of location data and populating the environment data file. An adapter application comprising computer code is generated that, when executed, allows the enterprise application to exchange messages with the messaging system.

Abstract: A method for configuring a computing device to use a communication protocol is provided. The method is performed by a computing device that includes a host processor coupled to a bus processor and to memory. The method includes receiving, by the host processor, a human-readable configuration file that includes parameters for communication using the communication protocol. The method additionally includes generating, by the host processor, at least one data structure based on the parameters in the human-readable configuration file. Additionally, the method includes providing, to the bus processor, memory location associated with the at least one data structure for use in communicating using the communication protocol.

Abstract: A haptic system which utilizes a combination of tactile and kinesthetic sensing allows a visually impaired person to sense visual and graphical information, such as graphs, figures, and images, on computer displays or printed material. An optical sensor is positioned on a person's hand, e.g., on the person's finger or fingers, or on the person's palm, or is positioned on a stylus used by the person. The optical sensor is traced over an image. When the sensor passes over or follows a location of color or an edge or point of contrast of the graphical information or image, e.g., a line graph, bar graph or pie chart, tactile feedback is provided to the user. The combination of the mechanical stimulation in the same area of the hand used in the sensing (i.e., being kinesthetic ally concordant) will allow the user to more easily and quickly ‘sense’ the shape or image presented on the display or paper.